Global artificial disc market is predicted to attain revenue of $3.3 billion by 2024, according to a market research report published by P&S Intelligence.
Cervical discs are expected to generate revenue of $2,479.6 million by 2024. Cervical discs are estimated to grow, as they facilitate early postoperative neck motion and reduce the chances of the cervical degenerative disc disease of adjacent segments of the cervical spine, post-surgery.
This growing trend is supported with the positive conclusions from several long terms studies as for example the following:
- Long-term Evaluation of Cervical Disc Arthroplasty with the Mobi-C© Cervical Disc: A Randomized, Prospective, Multicenter Clinical Trial with Seven-Year Follow-uphttps://www.ijssurgery.com/content/ijss/11/4/31.full.pdf
- Long-Term Clinical Experience with Selectively Constrained SECURE-C Cervical Artificial Disc for 1-Level Cervical Disc Disease: Results from Seven-Year Follow-Up of a Prospective, Randomized, Controlled Investigational Device Exemption Clinical Trial.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159663/
- New study first presented at the annual meeting of the International Society for the Advancement of Spinal Surgery (3-5 April 2019, Anaheim, CA). Jack E. Zigler, MD (Texas Health Center for Diagnostics and Surgery, Texas Back Institute, Plano, TX) reported results that “strongly support” the safety of Centinel Spine’s prodisc® C Cervical Total Disc Replacement System. In the study of 504 consecutive patients, Zigler and colleagues found no secondary surgery requirements for device failure and a relatively low reoperation rate of 5.5%—including the learning curve for every participating surgeon. The study encompassed results, specifically reoperation rates, for all consecutive patients receiving a prodisc C over a fifteen-year timeframe at a single center. https://centinelspine.press/2019/05/02/study-strongly-supporting-the-safety-of-centinel-spines-prodisc-c-cervical-total-disc-replacement-system-presented-at-isass/
Also, recently the cervical artificial disc market has been moving with several milestones in the last two years:
- Dec. 22, 2017– Centinel Spine, LLC (CS) announced the acquisition of the worldwide assets of the prodisc® Total Disc Replacement portfolio from DePuy Synthes Products, Inc. The prodisc® portfolio included prodisc® C and prodisc® L in the United States and prodisc® VIVO, prodisc® NOVA, prodisc® C, prodisc® L, and prodisc® O, along with DISCOVER™ Cervical outside the United States.
- March.15,2018–Orthofix International N.V. (NASDAQ:OFIX), announced that it has entered into a definitive agreement to acquire Spinal Kinetics Inc., a privately held developer and manufacturer of artificial cervical and lumbar discs.
- Feb. 7, 2019– Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, announced U.S. Food and Drug Administration (FDA) approval of the M6-C™ artificial cervical disc for patients suffering from cervical disc degeneration. The M6-C artificial cervical disc was developed by Spinal Kinetics, a company acquired by Orthofix in April 2018.
The leading players in the global ADR market today are Centinel Spine (Prodisc-C, Discovery) Globus Medical (Secure), Zimmer Biomet (Mobi-C), Orthofix (M6-C ) and Spineart (Baguera). Beyond these major players, the current market includes small- to mid-sized companies, many of which are focused on novel spine or spinal nonfusion devices.Please visit the ADR section to learn more about the 50 cervical discs that compete in this market: http://www.thespinemarketgroup.com/category/adr/
KEY DRIVERS OF THE MARKET
- Growing of the aging population that is driving the expansion of degenerative spinal diseases and disorders.
- Advantages over traditional spinal fusion procedures:Spinal fusion is currently considered the gold standard in degenerative disc disease treatment, accomplishing both deformity correction and stabilization. However, sequelae associated with a successful fusion procedure have driven attention towards non-fusion technologies, including artificial disc replacement (ADR), which are expected to challenge the growth of spinal fusion. ADR technologies are marketed for both the cervical and lumbar spine, and share the common goal of replacing the patient’s disc while often differing in their designs and materials. Compared to lumbar ADR, cervical ADR receives wider popularity at present due to more widely appreciated clinical effectiveness and growing demand for two-level cervical ADR procedures.
- FDA approvals and Improving the reimbursement scheme:
- North America is a major contributor to the global market for ADR, driven by an improving reimbursement scheme for cervical disc replacements and the recent FDA approval for another two-level cervical system. Fast growth is also expected in South America, as spine companies outside this region ramp up their market penetration efforts to promote cervical disc replacement and patients seek out more modern healthcare treatments. Although pricing pressures are being experienced in South America, the effects of these pressures are more strongly felt in other regions, stemming potential market growth. The developing markets in Asia-Pacific and the Middle East and Africa still rely heavily on patients to pay out of pocket for medical treatment, restricting access to expensive procedures such as ADR. Additionally, economic frailty in Europe has forced healthcare providers to focus on cost savings, again limiting the use of costly ADR systems.Despite these obstacles, medium to high growth is expected in ADR markets around the world as patients demand an improved quality of life. Preservation of spinal motion, less recurrence of reoperation, and the minimally invasive nature of the ADR procedure are appealing factors to patients and physicians alike, and are expected to drive adoption over the next five years. Although the market for spinal fusion will remain the most lucrative spine market in 2023, the market also has the potential for spinal nonfusion technologies such as ADR to surpass fusion as the gold standard treatment
Please, comments are welcome and do not hesitate to contact us by mail ([email protected]) if you have any issue related with this topic.